Fennec Pharmaceuticals (NASDAQ:FENC) Posts Earnings Results

Fennec Pharmaceuticals (NASDAQ:FENC) issued its quarterly earnings data on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26), Zacks reports. Fennec Pharmaceuticals had a negative return on equity of 39.41% and a net margin of 6.33%. The business had revenue of $7.26 million during the quarter, compared to analysts’ expectations of $13.67 million. During the same period in the previous year, the business earned ($0.21) earnings per share.

Fennec Pharmaceuticals Trading Up 3.8 %

FENC traded up $0.20 on Thursday, reaching $5.53. 53,180 shares of the company traded hands, compared to its average volume of 122,642. Fennec Pharmaceuticals has a one year low of $5.26 and a one year high of $11.92. The firm has a fifty day simple moving average of $6.33 and a two-hundred day simple moving average of $8.30. The company has a market cap of $151.12 million, a P/E ratio of 177.67 and a beta of 0.29. The company has a quick ratio of 6.72, a current ratio of 6.93 and a debt-to-equity ratio of 9.86.

Wall Street Analysts Forecast Growth

FENC has been the subject of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and set a $14.00 price target (down from $16.00) on shares of Fennec Pharmaceuticals in a research note on Tuesday. HC Wainwright dropped their price target on shares of Fennec Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, May 15th. Finally, Craig Hallum dropped their price target on shares of Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.